CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Akums Drugs and Pharmaceuticals Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Akums Drugs and Pharmaceuticals Ltd
Mangolpuri Ind. Area
Phase-I, Plot No. 131 to 133, Block-C
Phone: +91 1147511000p:+91 1147511000 NEW DELHI, 110034  India Ticker: AKUMSAKUMS
Business Summary
Akums Drugs and Pharmaceuticals Limited is an India-based pharmaceutical contract development and manufacturing company. It offers a comprehensive range of pharmaceutical products and services in India and overseas. It is focused on providing end-to-end product development and manufacturing solutions to its clients. Its segments include Contract Development and Manufacturing Operations (CDMO), Active Pharmaceutical Ingredient (API) and Branded and Generic formulations. CDMO segment includes the formulation research and development, preparation and regulatory filing of dossiers, manufacturing formulations on a contract basis, job work and testing services. API segment is engaged in the manufacture and sale of key starting materials, Intermediate and API products. Branded and Generic formulations segment is engaged in marketing and distribution of branded and generic pharmaceutical formulations. It has manufactured 4,146 commercialized formulations across over 60 dosage forms.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20243/31/2024Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Financial Officer SumeetSood 56 2/14/2022 2/14/2022
Compliance Officer, Company Secretary DharamvirMalik 40 11/6/2013 11/6/2013
Managing Director, Executive Director SandeepJain 57 6/30/2023 4/19/2004
7 additional Officers and Directors records available in full report.

General Information
Number of Employees: 7,388 (As of 3/31/2024)
Outstanding Shares: 153,105,000 (As of 9/30/2024)
Stock Exchange: NSE
Fax Number: +91 1127023256


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, December 2, 2024